drugset / Trial / NCT02169804

An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal

NCT02169804

Phase 1 Completed 24 enrolled Repros Therapeutics Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

• To determine and compare the pharmacokinetics (PK) of 3 doses of 25 mg Androxal in elderly healthy adult male subjects.

Timeline

Start
2014-08
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Androxal Unknown 25 mg

Indications

No indication recorded.